OMDAHealthcare · Health Information ServicesThe 12 Wall Street analysts covering Omada Health, Inc. hold a median 12-month price target of $28 — +53.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 12 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omada Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OMDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +53.0% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $35 |
| 11 Sept 2026 | Barclays | Maintains | Overweight | $25 → $27 |
| 11 Sept 2026 | BTIG | Reiterates | Buy | $35 |
| 11 Sept 2026 | Needham | Reiterates | Buy | $28 |
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | $27 → $32 |
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | $26 → $30 |
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 12 Aug 2026 | Baird | Maintains | Neutral | $15 → $25 |
| 12 Aug 2026 | Baird | Maintains | Neutral | — |
| 10 Aug 2026 | BTIG | Maintains | Buy | $30 → $35 |
| 10 Aug 2026 | BTIG | Maintains | Buy | — |
| 3 Aug 2026 | Barclays | Maintains | Overweight | — |
| 3 Aug 2026 | Barclays | Maintains | Overweight | $20 → $25 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $24 → $28 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 20 July 2026 | Citizens | Maintains | Market Outperform | $21 → $27 |
| 20 July 2026 | Citizens | Maintains | Market Outperform | — |
| 17 July 2026 | BTIG | Initiates | Buy | $30 |
| 17 July 2026 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMDA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Omada Health, Inc. returned −23.7% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 28% of US stocks
Cheaper than 19% of US stocks
Cheaper than 1% of US stocks
Higher than 84% of US stocks
Higher than 72% of US stocks
Higher than 85% of US stocks
Higher than 53% of US stocks
Higher than 51% of US stocks
Higher than 47% of US stocks
Higher than 43% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Omada Health, Inc. has a market value of $1.3B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $309.8M. The latest quarter grew 43.1% year on year.
Net income over the same four quarters: $4.3M, a 1.4% net margin.
Diluted earnings per share, trailing twelve months: $0.05.
Free cash flow in the twelve months to 30 June 2026: $17.1M, after $5.6M of capital spending.
Trailing P/E: 91.1×; forward P/E: 39.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Omada Health, Inc. employs 946 people — $327K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omada Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Omada Health said it will release its third-quarter 2026 financial results after market close on November 5, 2026, and hold a conference call at 4:30 p.m. ET that day. A live audio webcast will be available through its investor website.
Why it matters — OMDA watchers can note the scheduled date and time for the company’s results and management call.
Omada Health President Wei-Li Shao sold 9,418 shares for approximately $236,000. The open-market sale represented 3% of his direct equity holdings and was conducted under a pre-established Rule 10b5-1 trading plan.
Why it matters — A company president's insider share sale could draw attention from investors monitoring executive activity at Omada Health.
Omada Health, Inc. held an Analyst/Investor Day, and Seeking Alpha published the transcript of the event, covering management's discussion with analysts and investors. The transcript provides a record of the company's presentations and remarks from the occasion.
Why it matters — A transcript of the Analyst/Investor Day offers OMDA watchers direct access to management's commentary and the company's stated outlook as presented to investors.
Omada Health announced it will present updated long-term financial targets at its inaugural Investor Day, held today at the Four Seasons Hotel in New York. The virtual-first, between-visit healthcare provider is set to outline these targets to investors at the event.
Why it matters — Omada watchers will learn the company's updated long-term financial targets for the first time at its inaugural Investor Day, which could frame its growth outlook.
Omada Health announced a new independent cost savings model for its GLP-1 program. GlobalData published a report estimating greater disease reduction and higher cumulative gross medical cost savings—up to $11,142 per member over five years—compared to standard care.
Why it matters — A third-party analysis quantifying the clinical and economic value of Omada's GLP-1 program could support the company's market positioning and value proposition.
The 12 Wall Street analysts covering Omada Health, Inc. have a median 12-month price target of $28, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Omada Health, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omada Health, Inc. 85 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Omada Health, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +53.0% from the last close, and Ticker Nerd's factor model ranks Omada Health, Inc. 85 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omada Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.
Omada Health, Inc. returned -23.7% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Omada Health, Inc. Common Stock represents Omada Health, a digital health company focused on virtual care for chronic condition prevention and management.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026". Omada Health said it will release its third-quarter 2026 financial results after market close on November 5, 2026, and hold a conference call at 4:30 p.m. ET that day. A live audio webcast will be available through its investor website.
Omada Health, Inc. Common Stock represents Omada Health, a digital health company focused on virtual care for chronic condition prevention and management. The company provides evidence-based programs that combine coaching, connected devices, and digital tools to support people living with prediabetes, diabetes, hypertension, weight management needs, and musculoskeletal conditions. Omada Health works primarily with employers, health plans, pharmacy benefit managers, and health systems, helping them offer scalable care delivery outside traditional clinic settings. Its platform centers on ongoing, between-visit support designed to improve adherence, encourage healthier behaviors, and integrate with broader population health initiatives. Based in South San Francisco, California, Omada Health plays a notable role in the healthcare technology market by delivering virtual-first services that address long-term, high-prevalence conditions through personalized, technology-enabled care.
CEO Mr. Sean P. Duffy · 946 employees · United States · https://www.omadahealth.com
